LICENSE AND CO-DEVELOPMENT AGREEMENT by and among WYETH, acting through its WYETH PHARMACEUTICALS DIVISION, WYETH-WHITEHALL PHARMACEUTICALS, INC., WYETH- AYERST LEDERLE, INC., and PROGENICS PHARMACEUTICALS, INC. and PROGENICS PHARMACEUTICALS NEVADA,...Development Agreement • March 15th, 2006 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Co-Development Agreement (the “Agreement”) is entered into this 23rd day of December, 2005 (the “Effective Date”), by and among Wyeth, acting through its Wyeth Pharmaceuticals Division, a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, Wyeth-Whitehall Pharmaceuticals, Inc., a corporation having a principal place of business at Road No. 3, Kilometer 142.1, Guayama, Puerto Rico 00784, and Wyeth-Ayerst Lederle, Inc. a corporation having a principal place of business at 65th Infantry Road, Kilometer 9.7, Carolina, Puerto Rico 00987-4904 (collectively “Wyeth”) and Progenics Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591 (“Progenics”) and Progenics Pharmaceuticals Nevada, Inc., a corporation organized and existi
OPTION AND LICENSE AGREEMENTOption and License Agreement • March 15th, 2006 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
The University of Chicago, an Illinois not-for-profit corporation with principal offices at 5801 South Ellis Avenue, Chicago, Illinois, 60637 (the “University”), and UR Labs, Inc., a California corporation with principal offices at 10901 North Torrey Pines Road, La Jolla, California 92037 (“URL”), enter into this Agreement this ___ day of _________, 1985.
